DBV Technologies makes its 2024 Half-Year Financial Report available

DBV Technologies, a biopharmaceutical company listed on Euronext and Nasdaq, announced the publication of its 2024 Half-Year Financial Report. This report has been officially filed with the Financial Markets Authority in France.

The report in question, covering the period until June 30, 2024, is accessible on the DBV Technologies website as well as on that of the AMF. The public can also obtain a copy free of charge by requesting it by post or email.

DBV Technologies specializes in developing treatments for food allergies and other immunological conditions through its proprietary technology platform, Viaskin™. The company is currently conducting several clinical studies on the treatment of food allergies, including peanut allergies.